PQ
PQB.STU Pure Biologics Spólka Akcyjna
- Market cap
- EUR 55.3M
- P/E
- -
- P/B
- 1.52x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PQB.STU undervalued?
Graham numberThe Graham number of Pure Biologics Spólka Akcyjna cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pure Biologics Spólka Akcyjna fundamental analysis
No fundamental analysis for Pure Biologics Spólka Akcyjna yet.
Pure Biologics Spólka Akcyjna stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offe…
Full company profilePure Biologics Spólka Akcyjna financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pure Biologics Spólka Akcyjna annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.29M | 982K | 9.53M | 16.8M | 572K | 254K | 662K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.11M | 878K | 6.69M | 12.8M | 299K | -4.03M | -5.41M | -58.0K | -46.0K | -29.0K | -6.00K |
| Operating Income | -419K | -386K | -631K | -4.37M | -11.6M | -10.5M | -24.7M | -9.15M | -12.4M | -5.44M | -5.32M |
| EBITDA | - | -248K | -465K | -3.66M | -8.30M | -8.62M | -22.8M | -9.08M | -11.6M | -5.48M | -299M |
| Net Income | -433K | -413K | -689K | -4.55M | -11.8M | -11.8M | -25.6M | -35.7M | -19.4M | -9.82M | -300M |
| EPS | - | -0.35 | -0.59 | -2.75 | -7.11 | -5.22 | -11 | -11 | -2.21 | -0.87 | -25 |
| Balance Sheet | |||||||||||
| Total Assets | 952K | 1.33M | 6.58M | 21.8M | 18.9M | 47.2M | 33.0M | 22.7M | 2.34M | 4.94M | 51.6M |
| Total Liabilities | 640K | 1.12M | 4.36M | 14.6M | 21.8M | 7.70M | 14.7M | 20.8M | 15.5M | 19.1M | 216M |
| Shareholders' Equity | 312K | 210K | 2.22M | 7.21M | -2.89M | 39.5M | 18.3M | 1.89M | -13.1M | -14.1M | -164M |
| Cash & Short-term Investments | 220K | 267K | 196K | 13.9M | 8.96M | 6.18M | 2.26M | 3.61M | 313K | 10.0K | 45.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -710K | -2.85M | -2.49M | 6.92M | -1.35M | -24.0M | -17.4M | -23.3M | -10.8M | -6.25M | -8.48M |
| Capital Expenditure | 441K | 162K | 162K | 275K | 561K | 673K | 5.76M | 176K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -2.85M | -2.65M | 5.17M | -1.91M | -24.7M | -23.1M | -23.4M | -10.8M | -6.25M | -8.48M |
| Ratios | |||||||||||
| ROE | -138.9% | -196.7% | -31.0% | -63.0% | - | -29.8% | -139.9% | -1,885.6% | - | - | - |
| ROA | -45.5% | -31.1% | -10.5% | -20.9% | -62.1% | -24.9% | -77.6% | -157.0% | -829.5% | -198.8% | -582.6% |
| Net Profit Margin | -33.6% | -42.0% | -7.2% | -27.1% | -2,055.2% | -4,631.9% | -3,867.5% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Pure Biologics Spólka Akcyjna dividends
Pure Biologics Spólka Akcyjna has not paid dividends in the last 9 fiscal years.
Who owns Pure Biologics Spólka Akcyjna
- Insiders 72.43%
- Institutions 18.63%
- Public & others 8.94%
- Shares outstanding 226M
- Free float 10.7M
Pure Biologics Spólka Akcyjna company profile
- Company name
- Pure Biologics Spólka Akcyjna
- Ticker
- PQB.STU
- ISIN
- PLPRBLG00010
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- Szczytnicka 11, Wroclaw, Poland, 50-382
- Phone
- 48 57 000 2829
- Website
- multiqure.com
About Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis; and provides contract research for pharmaceutical and biotechnology companies. Pure Biologics S.A. was incorporated in 2010 and is headquartered in Wroclaw, Poland.
Pure Biologics Spólka Akcyjna management
3- Dr. Filip Jelen M.B.A., Ph.D.Co-founder & President of the Management Board
- Dr. Slawomir WojcikMember of Management Board
- Dr. Ewelina Swiderek Ph.D.Head of Project Management